Precision BioSciences has shared that the first participant in the FUNCTION_DMD clinical trial has received their investigational gene editing treatment, PBGENE-DMD. PBGENE-DMD delivers ARCUS nucleases via AAV9 to cut out exons 45-55 of the dystrophin gene, a therapeutic approach amenable to individuals with Duchenne with mutations in that region.
Link to press release: https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-commences-dosing-phase-12-function-dmd
The post Precision BioSciences has dosed the first individual with their novel gene editing approach for individuals with Duchenne mutations between exons 45 and 55 appeared first on CureDuchenne.